Related Experiment Video

Updated: Jan 28, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.6K

[PCSK9 inhibitors: What place in the management of dyslipidemia?]

Pierre Sabouret1, Michel Farnier2, Etienne Puymirat3

  • 1Pitié-Salpétrière Hospital and ACTION-Group, Heart Institute, Cardiology Department, 47-83, boulevard de l'Hôpital, 75013 Paris, France.

Presse Medicale (Paris, France : 1983)
|March 12, 2019
PubMed

Insights

PCSK9 inhibitors, like alirocumab and evolocumab, effectively lower LDL cholesterol. These treatments offer cardiovascular benefits for high-risk patients, even with statin therapy.

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiology

Background:

  • PCSK9 protein regulates LDL receptor activity.
  • PCSK9 mutations cause familial hypercholesterolemia or lower LDL cholesterol.
  • Loss-of-function PCSK9 mutations correlate with reduced heart disease risk.

Purpose of the Study:

  • To review the efficacy and safety of PCSK9 inhibitors.
  • To discuss the cardiovascular benefits of PCSK9 inhibition.
  • To outline European consensus guidelines for PCSK9 inhibitor candidates.

Main Methods:

  • Review of clinical trial data for PCSK9 inhibitors.
  • Analysis of genetic studies on PCSK9 function.
  • Synthesis of European consensus recommendations.

Main Results:

  • PCSK9 monoclonal antibodies are highly effective in reducing LDL-C.
  • Alirocumab and evolocumab show cardiovascular benefits alongside statins.
  • European guidelines identify specific patient groups for PCSK9 inhibitor therapy.

Conclusions:

  • PCSK9 inhibitors represent a significant advancement in managing hypercholesterolemia.
  • These therapies offer a valuable option for high-risk cardiovascular patients.
  • Targeted use of PCSK9 inhibitors is supported by clinical evidence and expert consensus.

More Related Videos

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

7.1K
Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
643
Impression Management Techniques I: Managing Appearances01:29

Impression Management Techniques I: Managing Appearances

Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
213
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
423
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K